Indian American business leader aims to build a world-class delivery and performance platform at leading medical technology ...
After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...
Travis Steed, the medical device analyst at Bank of America. Next up, we have Becton, Dickinson, Tom Polen, CEO; and Vitor Roque, the newly announced CFO. I think you've been to Vegas a couple of ...
On February 5, 2025, Becton, Dickinson and Company (BD) announced plans to separate its Biosciences and Diagnostic Solutions business into an independent entity. The Biosciences and Diagnostic ...
Chris DelOrefice, executive vice president and CFO of Becton, Dickinson plans to leave the company on Dec. 5 for “a new professional opportunity.” BD is currently searching for a new CFO to take over ...
10don MSN
BD forecasts FY 2026 adjusted EPS of $12.52-$12.72 while reaffirming low-single-digit revenue growth
Q2 fiscal 2026 Management view "We delivered a solid second quarter with revenue, adjusted margins and adjusted EPS all ahead of our expectations" (President, CEO & Chairman Thomas Polen), adding, ...
Becton, Dickinson and Co. is increasing its U.S. manufacturing capacity for essential medical devices, including syringes, needles and IV catheters. As part of a $10 million investment in 2024, new ...
FRANKLIN LAKES, N.J. & SAN DIEGO--(BUSINESS WIRE)--BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of laboratory automation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results